Alzheimer's Archives

Interview 2 Sep 2020

An Alzheimer’s Vaccine Challenged the Consensus for 25 Years

For decades, Alzheimer’s disease research focused on a hypothesis that has increasingly been contested. A team of scientists in Slovakia has been swimming against the tide since the beginning, going for an alternative approach that has only recently started gaining recognition. Research in Alzheimer’s disease has recently been plagued by intense disappointment. For over 25 […]

September 2, 2020 - 8 minutesmins - By Farhan Mitha

epigenetics review cambridge epigenetix oryzon1

News and Trends 9 Apr 2020

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in patients with Alzheimer’s disease and improved the experience of their caregivers in a phase IIa trial. At the same time, an Alzheimer’s vaccine developed by the Austrian biotech Axon Neuroscience has lowered a key blood biomarker of neurodegeneration by almost […]

April 9, 2020 - 4 minutesmins - By David Kirk

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune and Eli Lilly modified a deal signed in late 2018 to co-develop a small molecule treatment to slow the progression of Alzheimer’s disease. Specifically, the […]

March 24, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Feb 2020

EU Project Set up to Fight Alzheimer’s Disease with Lasers

A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no treatments approved that can slow the progression of neurodegenerative conditions, including Alzheimer’s and Huntington’s disease. Treatments approved to alleviate the symptoms only help a small […]

February 7, 2020 - 3 minutesmins - By Jonathan Smith

alzheimers disease treatment vivoryon therapeutics

News and Trends 24 Oct 2019

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […]

October 24, 2019 - 2 minutesmins - By Jonathan Smith

More News! 23 Sep 2019

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which Eli Lilly and AC Immune signed to develop drugs for Alzheimer’s and other neurodegenerative […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

astrocyte alzheimers disease astronautx blood london

Startup Scout 16 Aug 2019

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells

It’s time to go to London, UK, this week. The UK biotech AstronauTx is developing drugs that could slow the progress of Alzheimer’s disease by aiming at star-shaped cells in the brain called astrocytes. Mission: To develop small molecule drugs targeting astrocytes, whose inflammatory activity is linked to the development of Alzheimer’s disease. Alzheimer’s disease […]

August 16, 2019 - 4 minutesmins - By Jonathan Smith

small respiratory syncytial virus alzheimers disease sweden 1

News and Trends 28 May 2019

Viral Vaccines Could Be Weapons Against Alzheimer’s Disease

Scientists in Sweden have found that some viruses can increase the buildup of protein ‘plaques’ linked to Alzheimer’s disease, a discovery that could lead to new vaccines treating the condition. According to Kariem Ezzat, one of the lead researchers based in Stockholm University, the group is looking for industrial collaborators to develop vaccines against viruses […]

May 28, 2019 - 3 minutesmins - By Jonathan Smith

Best in Biotech 8 May 2019

Top 10 Biotechs in Lausanne

The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […]

May 8, 2019 - 7 minutesmins - By David Cox

bioarctic alzheimers disease plaques amyloid beta neurons Edited

More News! 25 Mar 2019

Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug

The failure of Biogen’s Alzheimer’s disease drug in a phase III trial last week caused BioArctic’s stock price to plummet by 35% on Nasdaq Stockholm. The Swedish company has just begun a phase III trial of its own Alzheimer’s treatment. Last week, Biogen and its pharma collaborator Eisai discontinued the phase III development of an […]

March 25, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 24 Dec 2018

Looking Back on 2018: Our 10 Most Popular Interviews

As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […]

December 24, 2018 - 8 minutesmins - By Helen Albert

More News! 29 Oct 2018

Plasma Replacement Therapy Promising in Alzheimer’s Patients

A blood plasma replacement therapy from Spanish company Grifols reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo. The researchers monitored the cognitive symptoms of 496 patients with Alzheimer’s disease in the Phase IIb/III trial. Over 14 months, the therapy had no effect in patients with mild Alzheimer’s, but the […]

October 29, 2018 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us